Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

Last year, Genentech, a global leader in the manufacture of genetically engineered drugs, had sales of about $5.5 billion. A “biotech drug” is one that uses a protein to treat a particular disorder: to make its protein-based drugs, which include cancer treatments and a human growth hormone, Genentech must grow vast quantities of therapeutic proteins in host cells and then harvest them.

The company can ferment approximately 280,000 liters of cell culture at any one time at its various manufacturing plants.

This photo essay illustrates the production process at Genentech’s South San Francisco plant, from the testing and fine-tuning of manufacturing techniques, to the fermentation of cells, to the purification of drugs that will be shipped around the world.

[Click here for the images.]

2 comments. Share your thoughts »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me